CA-ESRI
Esri , the global leader in location intelligence, today announced a joint initiative with AfroChampions , a Pan-African nonprofit that aims to promote policies that foster private-public collaboration for Africa's economic transformation. The goal of the initiative is to engage leaders in business, governments, the African Union, and other regional economic communities through dialogue and potential partnership building in applying geospatial technology and solutions.
This new partnership with AfroChampions seeks to contribute to sustainable economic development in Africa and promote the benefits of a shared geospatial infrastructure throughout the continent. As a majority of Africans still live in rural areas, geographic information system (GIS) technology can create new opportunities for growth, especially in critical fields such as health and telemedicine, land management, agriculture, and mobility.
The powerful mapping and data analytics that GIS provides forms a foundation for some of the most successful economic strategies that nations pursue today. This initiative will offer African governments and other organizations streamlined access to Esri's world-leading GIS technology and expertise, in addition to a broad network of regional partners.
"Given the impact of the COVID-19 pandemic and related crises, African leaders must fast-track the African Continental Free Trade Area [AfCFTA], which is our own recovery plan," said Dr. Edem Adzogenu, executive director of AfroChampions. "However, we need technologies, such as geospatial solutions, to operationalize the AfCFTA."
Over the long term, Esri's solutions will advance projects retained as part of AfroChampions Trillion Dollar Investment Framework, a 360-degree road map officially endorsed by the African Union and in which core enablers of the AfCFTA are transportation and connectivity; the removal of nontariff barriers; low-cost power; and enhanced value and industrialization in a modernized digital economy.
"At a time of economic uncertainty, we consider it part of our company's mission to coordinate and collaborate with partners like AfroChampions for initiatives that promote sustainable global development," said Sohail Elabd, general manager of Esri Middle East and Africa. "With the help of a network of action-oriented business and political leaders spreading across the entire continent, these initiatives can be instrumental in advancing the use of geospatial solutions for the public good around the world, from healthcare coverage to infrastructure support."
This partnership is part of Esri's ongoing commitment to its users and the broader geospatial community across Africa. It is closely aligned with key continental initiatives such as AfCFTA; the African Development Bank Strategy for 2013–2022; the United Nations 2030 Agenda for Sustainable Development; and the African Union Agenda 2063, which emphasizes the need for global Geospatial Information for Sustainable Development (GI4SD) management.
"Esri's support is timely," continued Adzogenu. "It can help us in many practical ways, like compiling data, identifying best practices that can be replicated from one country to another, defining the right locations for strategic infrastructure projects, or launching cross-border renewable projects."
Africa Geoportal , the continent's existing geospatial community platform built by Esri, will support the AfroChampions' virtual festival Boma of Africa as well as other ongoing community outreach activities.
To learn more about how Esri is partnering with Middle Eastern and African communities to empower them with location-based sustainable solutions to global challenges, visit esri.com/en-us/about/about-esri/mea .
About AfroChampions
The AfroChampions Initiative is a public-private partnership designed to galvanize African resources and institutions to drive Africa's economic integration and transformation. As a consequence, AfroChampions supports the emergence and success of African economic champions, which have a critical role in integrating African markets and accelerating the transformation of the continent and its global competitiveness. AfroChampions is headquartered in Accra, Ghana, and works with regional and global partners and governments, with the support of other corporate and institutional partners. AfroChampions has defined four pillars of activity, all aimed at supporting Africa's economic integration. These are
- Policy advocacy: Policy-shaping and advocacy on African integration and inclusive development, with a specific focus on advancing the African Continental Free Trade area, expected to create the largest single market globally in 2021.
- Mobilizing champions for impact: Building networks and partnerships of African private and public sector champions to collaborate on African transformation projects and initiatives.
- Facilitating investments: Driving investment in game-changing projects on the continent that accelerate integration and transformation.
- Building future champions: Building and promoting the next generation of African champion institutions, innovators, and leaders.
Learn more at www.afrochampions.com .
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005627/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom